Forest Expects Lexapro To Lead Market By ’05; Will Re-Launch In GAD In ’04
Executive Summary
Forest expects its anti-depressant Lexapro (escitalopram) to lead the selective serotonin reuptake inhibitor market by 2005
You may also be interested in...
Forest Lexapro “Re-Launch” For Generalized Anxiety Set For Mid-January
Forest will begin promotion of Lexapro for generalized anxiety disorder in mid-January
Forest Lexapro “Re-Launch” For Generalized Anxiety Set For Mid-January
Forest will begin promotion of Lexapro for generalized anxiety disorder in mid-January
Forest Lexapro Strategy Changes: Reps Encouraging Switches From Celexa
Forest is restructuring its sales representative compensation program to encourage switches from the company's antidepressant Celexa to the follow-on selective serotonin reuptake inhibitor Lexapro
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: